AHK-Cu Doses Used in Published Studies: What Researchers Reported

Answer first: the verified literature summarised on this page does not contain a human clinical dosing schedule for AHK-Cu (the alanine–histidine–lysine tripeptide complexed with copper). The published copper-tripeptide record that is indexed here concentrates on the related tripeptide GHK and its copper complex, on copper-peptide hydrogels tested in wound models, and on broader reviews of peptide therapies in sports medicine and orthopaedics. Where doses or concentrations exist in that work, they are properties of a laboratory preparation — a cell-culture medium, a topical vehicle, a hydrogel dressing — not instructions that can be scaled to a person.

This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decision. Nothing here describes a protocol, and no quantity below should be read as a target.

Why this page contains no dosage chart

A dosage chart implies three things the copper-tripeptide literature does not supply: a defined route with characterised absorption, a dose–response curve in humans, and a safety margin established in people. The reviews available here instead described mechanisms and open questions. A 2018 review examined the regenerative and protective actions of the GHK-Cu peptide in the light of new gene-expression data (PMID 29986520), and a 2020 review discussed the potential of GHK as an anti-aging peptide rather than a validated dosing regimen (PMID 35083444). Neither paper established a human dose, and neither addressed AHK-Cu as a separately dosed agent.

Because of that, the honest summary is a negative finding. Researchers have characterised what copper tripeptides appear to do in models; they have not published the kind of escalating-dose human trials that generate dosing tables. Presenting invented numbers as "studied doses" would misrepresent the record.

AHK-Cu versus GHK-Cu: why the substitution matters for dose talk

AHK-Cu and GHK-Cu are both short copper-binding tripeptides, differing at the first residue (alanine versus glycine). That single-residue change alters copper coordination geometry, stability and how much free versus bound copper a preparation carries, which is exactly the variable that determines biological behaviour in copper-peptide systems. Analytical work on a different copper-binding peptide illustrated how much instrumentation is needed to pin down copper coordination, with researchers characterising the copper peptide hepcidin-25 by LC-MS/MS and NMR (PMID 30072660). The practical consequence is that dose figures from GHK-Cu work cannot be treated as AHK-Cu figures, and figures for one copper-loading ratio cannot be treated as figures for another.

What the copper-tripeptide studies actually administered

Topical and cosmetic research

The topical route dominates the human-facing end of this literature. A 2025 review examined topically applied GHK as an anti-wrinkle peptide and set out the advantages, problems and prospects of that route, including the delivery problems that complicate any attempt to define an effective applied amount (PMID 39963574). Earlier work described the human tripeptide GHK in the context of tissue remodeling, framing it as a signalling molecule studied in remodeling processes rather than a dosed drug (PMID 18644225). In topical research the meaningful variable is the concentration inside a specific formulation applied to a specific skin model, which is not interchangeable with a systemic dose.

Wound-model research using delivery materials

Two recent studies delivered copper peptides inside engineered materials rather than as free solutions. Researchers reported that a food-derived tripeptide–copper self-healing hydrogel promoted infected wound healing in their experimental model (PMID 39902373), and a 2025 study reported that a dimeric copper peptide incorporated into a hydrogel promoted diabetic wound healing in its model system (PMID 40592840). In both cases the peptide was one component of a composite material with its own release kinetics; the amount loaded into the gel describes the device, not a dose a person could reproduce.

Copper chemistry as a bioactivity driver

Copper-peptide combinations are not inert carriers. A 2024 study reported that copper-induced supramolecular peptide assemblies produced multi-pathway cell death and tumour inhibition in the systems tested (PMID 38837577). That work involved different peptides and different design goals from AHK-Cu cosmetic research, but it makes a relevant point about dose reasoning: with copper complexes, higher concentrations can shift a preparation from signalling effects toward cytotoxic ones, so extrapolating upward from a low laboratory concentration is not a conservative assumption.

Study-by-study: what was reported, and what was not

Read as a set, the pattern is consistent: the studies reported formulations, models and outcomes, and the reviews reported mechanisms and unresolved questions. No entry in this set supplies a human AHK-Cu dose, duration or frequency.

Why study doses do not translate into recommendations

Even in fields where numbers are abundant, moving from a study figure to a person requires steps that copper-tripeptide research has not taken.

• Route changes everything. A concentration in a cream, a load in a hydrogel dressing and an injected quantity are not the same measurement. The topical review specifically identified delivery problems as an unresolved issue for applied GHK (PMID 39963574).
• Vehicle and material dictate exposure. Both hydrogel studies delivered peptide from a material with its own release profile (PMID 39902373, PMID 40592840), so the loaded amount cannot be separated from the carrier.
• Species and model differ from patients. Reviews of GHK and GHK-Cu drew on cell and animal data (PMID 29986520, PMID 35083444), and animal-to-human conversion requires pharmacokinetic data that the record here does not provide for AHK-Cu.
• Copper load is a separate variable. Copper coordination needs explicit analytical characterisation, as shown in the LC-MS/MS and NMR study of a copper peptide (PMID 30072660), and copper-driven cytotoxicity has been reported in other peptide systems (PMID 38837577).
• No human dose-finding exists here. Without escalation studies and endpoints in people, there is no lowest effective amount and no ceiling to reason from.

How peptide reviews in sports medicine framed dosing gaps

Recent clinical reviews addressed the wider category of peptides marketed for musculoskeletal and performance purposes. A 2026 review of therapeutic peptides in orthopaedics set out applications, challenges and future directions for the field (PMID 41490200), and a 2026 primer on injectable peptide therapy was written for orthopaedic and sports medicine physicians assessing these agents (PMID 41476424). A further 2026 review examined the safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance (PMID 41966639), while another 2026 review covered peptide supplements and their therapeutic applications in sports medicine (PMID 42578445). The recurring theme across these papers is that many peptides circulating in consumer and compounded channels lack approval and lack the trial base that would define dosing.

That regulatory context matters for AHK-Cu specifically. Research-use-only material is sold for laboratory work and is not an approved drug product, and cosmetic ingredient use is governed by different rules from drug approval. Numbers that appear in ingredient specifications or laboratory catalogues are not clinical doses.

Adverse Events in Copper-Peptide Research: What Studies Report

The verified record here does not include a human safety trial of AHK-Cu, so there is no reported adverse-event profile with incidence rates to summarise. What the literature does report is that copper-peptide complexes can be biologically potent: researchers reported that copper-induced supramolecular peptide assemblies triggered multi-pathway cell death and tumour inhibition in their models (PMID 38837577), which is a cautionary signal about assuming copper complexes are benign at arbitrary concentrations. Clinical reviews of peptide therapies for musculoskeletal and athletic use explicitly examined safety alongside efficacy for both approved and unapproved products (PMID 41966639) and framed injectable peptide use as an area requiring physician-level assessment (PMID 41476424). Reviews of GHK and GHK-Cu focused on regenerative signalling and open mechanistic questions rather than documented toxicity thresholds (PMID 29986520).

What better evidence would look like

1. Analytical characterisation of the exact AHK-Cu complex tested, including copper stoichiometry, in the manner applied to other copper peptides (PMID 30072660).
2. Pharmacokinetic data for a defined route, addressing the delivery limitations raised for topical tripeptides (PMID 39963574).
3. Dose-ranging animal work with reported durations and endpoints, rather than mechanistic review summaries (PMID 35083444).
4. Controlled human trials with prespecified outcomes and adverse-event capture, the standard that clinical reviewers applied when separating approved from unapproved peptide therapies (PMID 41966639).

Until those steps exist, any AHK-Cu "dosing chart" circulating online is an extrapolation rather than a finding. The most accurate statement the literature supports is that copper tripeptides have been studied as signalling molecules in remodeling and wound contexts (PMID 18644225, PMID 39902373), and that the dose question for AHK-Cu in humans remains unanswered.

References

• Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data (International Journal of Molecular Sciences, 2018)
• The potential of GHK as an anti-aging peptide (Aging Pathobiology and Therapeutics, 2020)
• Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective (BioImpacts, 2025)
• The human tri-peptide GHK and tissue remodeling (Journal of Biomaterials Science, Polymer Edition, 2008)
• Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing (Biomaterials Research, 2025)
• Dimeric copper peptide incorporated hydrogel for promoting diabetic wound healing (Nature Communications, 2025)
• Investigations of the Copper Peptide Hepcidin-25 by LC-MS/MS and NMR (International Journal of Molecular Sciences, 2018)
• Copper-Induced Supramolecular Peptide Assemblies for Multi-Pathway Cell Death and Tumor Inhibition (Angewandte Chemie International Edition, 2024)
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (The American Journal of Sports Medicine, 2026)
• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance (Sports Medicine, 2026)
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine (The American Journal of Sports Medicine, 2026)